|
Name |
Lauric Acid
|
Molecular Formula | C12H24O2 | |
IUPAC Name* |
dodecanoic acid
|
|
SMILES |
CCCCCCCCCCCC(=O)O
|
|
InChI |
InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)
|
|
InChIKey |
POULHZVOKOAJMA-UHFFFAOYSA-N
|
|
Synonyms |
lauric acid; DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Laurostearic acid; Vulvic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Ninol AA62 Extra; Wecoline 1295; Hydrofol acid 1255; Hydrofol acid 1295; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Univol U-314; Lauric acid, pure; Lauric acid (natural); ABL; Undecane-1-carboxylic acid; NSC-5026; FEMA No. 2614; Laurinsaeure; C12:0; C-1297; n-Dodecanoate; Philacid 1200; Dodecanoic Acid Anion; CHEBI:30805; Prifrac 2920; Lunac L 70; Emery 651; MFCD00002736; DAO; CH3-[CH2]10-COOH; NSC5026; 1160N9NU9U; dodecylate; laurostearate; vulvate; DODECANOIC ACID (LAURIC ACID); DSSTox_CID_1590; 1-undecanecarboxylate; DSSTox_RID_76223; DSSTox_GSID_21590; CAS-143-07-7; SMR001253907; CCRIS 669; HSDB 6814; EINECS 205-582-1; BRN 1099477; dodecanic acid; lauric-acid; UNII-1160N9NU9U; Acide Laurique; AI3-00112; n-Dodecanoicacid; 3uil; Lauric acid (NF); Lauric Acid 652; DODECANOICACID; Kortacid 1299; Lauric Acid, Reagent; Nissan NAA 122; Emery 650; Lunac L 98; Prifac 2920; Univol U 314; Dodecanoic acid, 98%; Dodecanoic acid, 99%; Dodecanoic (Lauric) acid; LAURIC ACID [MI]; bmse000509; LAURIC ACID [FCC]; EC 205-582-1; LAURIC ACID [FHFI]; LAURIC ACID [INCI]; SCHEMBL5895; NCIOpen2_009480; 4-02-00-01082 (Beilstein Handbook Reference); MLS002177807; MLS002415737; WLN: QV11; Dodecanoic acid (lauric acid); LAURIC ACID [USP-RS]; LAURIC ACID [WHO-DD]; Dodecanoic acid, >=99.5%; Edenor C 1298-100; DODECANOIC ACID [HSDB]; CHEMBL108766; GTPL5534; Lauric acid-1,2-[13C2]; DTXSID5021590; Lauric acid-1,12-[13C2]; HMS2268C14; HMS3649N06; HY-Y0366; STR08039; ZINC1529498; Dodecanoic acid, analytical standard; Lauric acid, >=98%, FCC, FG; Tox21_202149; Tox21_303010; BDBM50180948; LMFA01010012; s4726; STL281860; AKOS000277433; Lauric acid-1,2,3,4-[13C4]; CCG-266587; DB03017; FA 12:0; NCGC00090919-01; NCGC00090919-02; NCGC00090919-03; NCGC00256486-01; NCGC00259698-01; AC-16451; BP-27913; Dodecanoic acid, >=99% (GC/titration); LAU; Dodecanoic acid, purum, >=96.0% (GC); Lauric acid, natural, >=98%, FCC, FG; CS-0015078; FT-0625572; FT-0695772; L0011; EN300-19951; A16350; C02679; D10714; A808010; Q422627; SR-01000838338; J-007739; SR-01000838338-3; F0001-0507; LAURIC ACID (CONSTITUENT OF SAW PALMETTO) [DSC]; Z104476194; 76C2A2EB-E8BA-40A6-8032-40A98625ED7B; Lauric acid, European Pharmacopoeia (EP) Reference Standard; Lauric acid, United States Pharmacopeia (USP) Reference Standard; Lauric Acid, Pharmaceutical Secondary Standard; Certified Reference Material
|
|
CAS | 143-07-7 | |
PubChem CID | 3893 | |
ChEMBL ID | CHEMBL108766 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 200.32 | ALogp: | 4.2 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 37.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 14 | QED Weighted: | 0.522 |
Caco-2 Permeability: | -4.898 | MDCK Permeability: | 0.00003050 |
Pgp-inhibitor: | 0.064 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.839 |
30% Bioavailability (F30%): | 0.979 |
Blood-Brain-Barrier Penetration (BBB): | 0.477 | Plasma Protein Binding (PPB): | 96.81% |
Volume Distribution (VD): | 0.315 | Fu: | 1.96% |
CYP1A2-inhibitor: | 0.149 | CYP1A2-substrate: | 0.253 |
CYP2C19-inhibitor: | 0.044 | CYP2C19-substrate: | 0.399 |
CYP2C9-inhibitor: | 0.231 | CYP2C9-substrate: | 0.982 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.09 |
CYP3A4-inhibitor: | 0.012 | CYP3A4-substrate: | 0.03 |
Clearance (CL): | 2.259 | Half-life (T1/2): | 0.772 |
hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.034 |
Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.05 | Maximum Recommended Daily Dose: | 0.016 |
Skin Sensitization: | 0.643 | Carcinogencity: | 0.099 |
Eye Corrosion: | 0.98 | Eye Irritation: | 0.986 |
Respiratory Toxicity: | 0.748 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000270 | 0.923 | D0Z5BC | 0.596 | ||||
ENC000378 | 0.867 | D0O1PH | 0.591 | ||||
ENC000088 | 0.846 | D0XN8C | 0.556 | ||||
ENC000466 | 0.813 | D07ILQ | 0.547 | ||||
ENC000399 | 0.773 | D05ATI | 0.536 | ||||
ENC000472 | 0.773 | D0E4WR | 0.510 | ||||
ENC001228 | 0.773 | D0O1TC | 0.478 | ||||
ENC000263 | 0.769 | D0Z5SM | 0.476 | ||||
ENC000050 | 0.765 | D0I4DQ | 0.440 | ||||
ENC000260 | 0.723 | D0UE9X | 0.433 |